PD-1 and PD-L1 Inhibitors Market by Application and Geography - Forecast and Analysis 2021-2025

  • Published: Jan 2022
  • Pages: 120
  • SKU: IRTNTR71931
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The PD-1 and PD-L1 inhibitors market share is expected to increase by USD 29.97 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 19.11%.

This PD-1 and PD-L1 inhibitors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers PD-1 and PD-L1 inhibitors market segmentation by application (solid tumors and blood-related tumors) and geography (North America, Europe, Asia, and ROW). The PD-1 and PD-L1 inhibitors market report also offers information on several market vendors, including Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc. among others.

What will the PD-1 and PD-L1 Inhibitors Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the PD-1 and PD-L1 Inhibitors Market Size for the Forecast Period and Other Important Statistics

 

PD-1 and PD-L1 Inhibitors Market: Key Drivers and Challenges

The reduction in cancer mortality rate is notably driving the PD-1 and PD-L1 inhibitors market growth, although factors such as the availability of alternative therapies may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the PD-1 and PD-L1 inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key PD-1 and PD-L1 Inhibitors Market Driver

The lack of approved therapies for cancer in the past led to a high mortality rate. However, the market has witnessed a significant decrease in mortality rate owing to the increasing approvals of novel cancer therapies in recent years. While underdeveloped economies such as Niger continue to have high mortality rates, developed countries such as the US, the UK, and Canada have witnessed a significant decrease. The reduction in the mortality rate of cancer is largely due to the availability of novel drugs, including PD-1 and PD-L1 inhibitors. This proven efficacy of the cancer drugs leads to a high patient adherence ratio, thereby driving the market growth. The reducing mortality rates of cancer and the increasing adoption rates of PD-1 and PD-L1 inhibitors are encouraging vendors in the market to spend heavily on research and development (R&D) of novel drugs, which is expected to add significant value to the PD-1 and PD-L1 inhibitors market during the forecast period. 

Key PD-1 and PD-L1 Inhibitors Market Challenge

Despite the proven efficacy of PD-1 and PD-L1 inhibitors in the treatment of various types of solid tumors and blood-related tumors, the market faces a heavy threat from the presence of alternative therapies. The increasing prevalence of cancer has resulted in an urgent need for the development of more advanced therapies to treat these indications. As a result, various vendors have started developing therapies for inhibiting PARP and HER-2. These therapies are called targeted anti-cancer therapies, in which the drug works on inhibiting the growth of the cancer-causing cell in the body. There are multiple targeted therapies approved for the treatment of various types of cancer. The global pharmaceutical market has also witnessed the advent of regenerative therapies such as CAR T-cell therapy and gene therapy for the treatment of cancer. The curative nature of regenerative therapies poses a huge threat to the global PD-1 and PD-L1 inhibitors market, and the expected approval of these therapies during the forecast period is expected to increase the threat, leading to less preference for PD-1 and PD-L1 inhibitors.

This PD-1 and PD-L1 market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major PD-1 and PD-L1 Inhibitors Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Agenus Inc.
  • Amgen Inc.
  • AnaptysBio Inc.
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bristol-Myers Squibb Co.
  • Checkpoint Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck and Co. Inc.
  • Pfizer Inc.

 

This statistical study of the PD-1 and PD-L1 inhibitors market encompasses successful business strategies deployed by the key vendors. The PD-1 and PD-L1 inhibitors market is fragmented and the vendors are entering into strategic alliances to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The PD-1 and PD-L1 market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for PD-1 and PD-L1 Inhibitors Market?

For more insights on the market share of various regions Request for a FREE sample now!

51% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for PD-1 and PD-L1 inhibitors in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.

This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Application Segments in the PD-1 and PD-L1 Inhibitors Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The PD-1 and PD-L1 inhibitors market share growth by the solid tumors segment will be significant during the forecast period.  The global PD-1 and PD-L1 inhibitors market has witnessed a significant increase in the approval of drugs for the treatment of various solid tumors in the last four years. This is primarily due to the high efficacy of PD-1 and PD-L1 inhibitors in blocking the cancer cells pathway and helping the T-cells to fight against the cancer-causing cells. The recent approval of IMFINZI, developed by AstraZeneca, for the treatment of urogenital cancer is expected to contribute heavily to the growth of the solid tumors segment.

This report provides an accurate prediction of the contribution of all the segments to the growth of the PD-1 and PD-L1 inhibitors market size and actionable market insights on post COVID-19 impact on each segment.

 

PD-1 and PD-L1 Inhibitors Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 19.11%

Market growth 2021-2025

$ 29.97 billion

Market structure

Fragmented

YoY growth (%)

18.40

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 51%

Key consumer countries

US, Germany, UK, Canada, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this PD-1 and PD-L1 Inhibitors Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive PD-1 and PD-L1 inhibitors market growth during the next five years
  • Precise estimation of the PD-1 and PD-L1 inhibitors market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the PD-1 and PD-L1 inhibitors industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of PD-1 and PD-L1 inhibitors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

Executive Summary

    Market Landscape

    • Market ecosystem
    • Value chain analysis

    Market Sizing

    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025

    Five Forces Analysis

    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition

    Market Segmentation by Application

    • Market segments
    • Comparison by Application
    • Solid tumors - Market size and forecast 2020-2025
    • Blood-related tumors - Market size and forecast 2020-2025
    • Market opportunity by Application

    Customer landscape

      Geographic Landscape

      • Geographic segmentation
      • Geographic comparison
      • North America - Market size and forecast 2020-2025
      • Europe - Market size and forecast 2020-2025
      • Asia - Market size and forecast 2020-2025
      • ROW - Market size and forecast 2020-2025
      • Key leading countries
      • Market opportunity by geography
      • Market drivers
      • Market challenges
      • Market trends

      Vendor Landscape

      • Vendor landscape
      • Landscape disruption

      Vendor Analysis

      • Vendors covered
      • Market positioning of vendors
      • Agenus Inc.
      • Amgen Inc.
      • AnaptysBio Inc.
      • AstraZeneca Plc
      • BeiGene Ltd.
      • Bristol-Myers Squibb Co.
      • Checkpoint Therapeutics Inc.
      • F. Hoffmann-La Roche Ltd.
      • Merck and Co. Inc.
      • Pfizer Inc.

      Appendix

      • Scope of the report
      • Currency conversion rates for US$
      • Research methodology
      • List of abbreviations

      Research Framework

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      TechnavioINFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases
      Technavio

      TechnavioDATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts
      Technavio

      TechnavioREPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape
      Interested in this report?
      Get your FREE sample now!
      The pd-1 and pd-l1 inhibitors market growth will increase by $29971.34 million during 2020-2025.
      The pd-1 and pd-l1 inhibitors market is expected to grow at a CAGR of 19.11% during 2020-2025.
      Technavio has segmented the pd-1 and pd-l1 inhibitors market by application (Solid tumors and Blood-related tumors) and geographic (North America, Europe, Asia, and ROW).
      Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Pfizer Inc. are a few of the key vendors in the pd-1 and pd-l1 inhibitors market.
      North America will register the highest growth rate of 51.41% among the other regions. Therefore, the pd-1 and pd-l1 inhibitors market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
      The key factors driving the pd-1 and pd-l1 inhibitors market growth are:
      • Reduction in cancer mortality rate
      The pd-1 and pd-l1 inhibitors market vendors should focus on grabbing business opportunities from the solid tumors segment as it accounted for the largest market share in the base year.
      Safe and Secure SSL Encrypted
      Technavio

      Single User:

      2500 USD

      Technavio Get the report (PDF) sent to your email within minutes.

      Subscribe & Save

      Get lifetime access to our
      Technavio Insights

      Want to customize this report?

      This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

      We offer $1000 worth of FREE customization at the time of purchase
      Technavio
      Enquire Before Buying
      1. Home
      2. Health Care
      3. Published Report
      17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>